The Role of Ketogenic Diet in the Treatment of Neurological Diseases
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Over a hundred years of study on the favourable effect of ketogenic diets in the treatment of epilepsy have contributed to a long-lasting discussion on its potential influence on other neurological diseases. A significant increase in the number of scientific studies in that field has been currently observed. The aim of this paper is a widespread, thorough analysis of the available scientific evidence in respect of the role of the ketogenic diet in the therapy of neurological diseases such as: epilepsy, Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis (MS) and migraine. A wide range of the mechanisms of action of the ketogenic diet has been demonstrated in neurological diseases, including, among other effects, its influence on the reduction in inflammatory conditions and the amount of reactive oxygen species (ROS), the restoration of the myelin sheath of the neurons, the formation and regeneration of mitochondria, neuronal metabolism, the provision of an alternative source of energy for neurons (ketone bodies), the reduction in glucose and insulin concentrations, the reduction in amyloid plaques, the induction of autophagy, the alleviation of microglia activation, the reduction in excessive neuronal activation, the modulation of intestinal microbiota, the expression of genes, dopamine production and the increase in glutamine conversion into GABA. The studies discussed (including randomised controlled studies), conducted in neurological patients, have stressed the effectiveness of the ketogenic diet in the treatment of epilepsy and have demonstrated its promising therapeutic potential in Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis (MS) and migraine. A frequent advantage of the diet was demonstrated over non-ketogenic diets (in the control groups) in the therapy of neurological diseases, with simultaneous safety and feasibility when conducting the nutritional model.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Feigin, V. L., Nichols, E., Alam, T., Bannick, M. S., Beghi, E., Blake, N., Culpepper, W. J., Dorsey, E. R., Elbaz, A., Ellenbogen, R. G., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30499-x · Cited by 5,644
Bloem, B. R., Okun, M. S., & Klein, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00218-x · Cited by 3,920
Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.018 · Cited by 3,622
Oxidative DNA damage: mechanisms, mutation, and disease
Cooke, M. S., Evans, M. D., Dizdaroglu, M., & Lunec, J. (2003) · The FASEB Journal · doi:10.1096/fj.02-0752rev · Cited by 3,245
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871
Suppression of Oxidative Stress by β-Hydroxybutyrate, an Endogenous Histone Deacetylase Inhibitor
Shimazu, T., Hirschey, M. D., Newman, J., He, W., Shirakawa, K., Le Moan, N., Grueter, C. A., Lim, H., Saunders, L. R., Stevens, R. D., et al. (2013) · Science · doi:10.1126/science.1227166 · Cited by 1,777
Neuroinflammation: The Devil Is in the Details
DiSabato, D. J., Quan, N., & Godbout, J. P. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13607 · Cited by 1,640
The clinical symptoms of Parkinson's disease.
Sveinbjornsdottir, S. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13691 · Cited by 1,410
Alzheimer’s disease is type 3 diabetes—Evidence reviewed
de la Monte, S. M., & Wands, J. R. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200619 · Cited by 1,158
Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology
Simon, D. K., Tanner, C. M., & Brundin, P. (2020) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2019.08.002 · Cited by 1,114
The Gut Microbiota Mediates the Anti-Seizure Effects of the Ketogenic Diet
Olson, C. A., Vuong, H. E., Yano, J. M., Liang, Q. Y., Nusbaum, D. J., & Hsiao, E. Y. (2018) · Cell · doi:10.1016/j.cell.2018.04.027 · Cited by 1,057
Beyond weight loss: a review of the therapeutic uses of very-low-carbohydrate (ketogenic) diets
Paoli, A., Rubini, A., Volek, J. S., & Grimaldi, K. A. (2013) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2013.116 · Cited by 885
The Epidemiology of Alzheimer's Disease Modifiable Risk Factors and Prevention
Zhang, X.-X., Tian, Y., Wang, Z.-T., Ma, Y.-H., Tan, L., & Yu, J.-T. (2021) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2021.15 · Cited by 789
Burch, R. C., Buse, D. C., & Lipton, R. B. (2019) · Neurologic Clinics · doi:10.1016/j.ncl.2019.06.001 · Cited by 741
D-β-Hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease
Tieu, K., Perier, C., Caspersen, C., Teismann, P., Wu, D.-C., Yan, S.-D., Naini, A., Vila, M., Jackson-Lewis, V., Ramasamy, R., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318797 · Cited by 497
The molecular pathophysiology of concussive brain injury
Barkhoudarian, G., Hovda, D. A., & Giza, C. C. (2011) · Clinics in Sports Medicine · doi:10.1016/j.csm.2010.09.001 · Cited by 492
Neuroprotective and disease-modifying effects of the ketogenic diet
Gasior, M., Rogawski, M. A., & Hartman, A. L. (2006) · Behavioural Pharmacology · doi:10.1097/00008877-200609000-00009 · Cited by 445
Johnstone, A. M., Horgan, G. W., Murison, S. D., Bremner, D. M., & Lobley, G. E. (2008) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/87.1.44 · Cited by 440
Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection
Patone, M., Handunnetthi, L., Saatci, D., Pan, J., Katikireddi, S. V., Razvi, S., Hunt, D., Mei, X. W., Dixon, S., Zaccardi, F., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01556-7 · Cited by 394
Kashiwaya, Y., Bergman, C., Lee, J.-H., Wan, R., King, M. T., Mughal, M. R., Okun, E., Clarke, K., Mattson, M. P., & Veech, R. L. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.11.023 · Cited by 363
Microbiome-Gut-Brain Axis and Toll-Like Receptors in Parkinson’s Disease
Caputi, V., & Giron, M. C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061689 · Cited by 338
A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer's disease
Van der Auwera, I., Wera, S., Van Leuven, F., & Henderson, S. T. (2005) · Nutrition & Metabolism · doi:10.1186/1743-7075-2-28 · Cited by 307
Role of ketogenic diets in neurodegenerative diseases (Alzheimer's disease and Parkinson's disease)
Włodarek, D. (2019) · Nutrients · doi:10.3390/nu11010169 · Cited by 301
Low-fat versus ketogenic diet in Parkinson's disease: A pilot randomized controlled trial
Phillips, M. C. L., Murtagh, D. K. J., Gilbertson, L. J., Asztely, F. J. S., & Lynch, C. D. P. (2018) · Movement Disorders · doi:10.1002/mds.27390 · Cited by 292
Muscogiuri, G., El Ghoch, M., Colao, A., Hassapidou, M., Yumuk, V., Busetto, L., & Obesity Management Task Force (OMTF) of the European Association for the Study of Obesity (EASO) (2021) · Obesity Facts · doi:10.1159/000515381 · Cited by 289
Biomarkers for Parkinson’s Disease: Recent Advancement
Lotankar, S., Prabhavalkar, K. S., & Bhatt, L. K. (2017) · Neuroscience Bulletin · doi:10.1007/s12264-017-0183-5 · Cited by 282
Marosi, K., Kim, S. W., Moehl, K., Scheibye‐Knudsen, M., Cheng, A., Cutler, R., Camandola, S., & Mattson, M. P. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13868 · Cited by 242
Intermittent Fasting: A Heart Healthy Dietary Pattern?
Dong, T. A., Sandesara, P. B., Dhindsa, D. S., Mehta, A., Arneson, L. C., Dollar, A. L., Taub, P. R., & Sperling, L. S. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.03.030 · Cited by 240
Yuan, X., Wang, J., Yang, S., Gao, M., Cao, L., Li, X., Hong, D., Tian, S., & Sun, C. (2020) · Nutrition & Diabetes · doi:10.1038/s41387-020-00142-z · Cited by 240
The ketogenic diet and brain metabolism of amino acids: Relationship to the anticonvulsant effect
Yudkoff, M., Daikhin, Y., Melø, T. M., Nissim, I., Sonnewald, U., & Nissim, I. (2007) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.27.061406.093722 · Cited by 202
Choi, Y. J., Jeon, S.-M., & Shin, S. (2020) · Nutrients · doi:10.3390/nu12072005 · Cited by 193 · cited 1×
“Taking into account the strongly hypoglycaemic effect of a ketogenic diet and the evident insulin-concentration-reducing effect [51,52], it seems reasonable that a ketogenic diet would have a favourable effect on the prevention of the deposition of amyloid plaques or a reduction in their number.”
BackgroundDysfunction of the blood–brain barrier in Alzheimer's disease: Evidence from human studies
Kurz, C., Walker, L., Rauchmann, B., & Perneczky, R. (2022) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12782 · Cited by 183
Ketosis and brain handling of glutamate, glutamine, and GABA
Yudkoff, M., Daikhin, Y., Horyn, O., Nissim, I., & Nissim, I. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01841.x · Cited by 139
Ketogenic Medium Chain Triglycerides Increase Brain Energy Metabolism in Alzheimer’s Disease
Croteau, E., Castellano, C.-A., Richard, M. A., Fortier, M., Nugent, S., Lepage, M., Duchesne, S., Whittingstall, K., Turcotte, É. E., Bocti, C., et al. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180202 · Cited by 135
Ketogenic diets and physical performance
Phinney, S. D. (2004) · Nutrition & Metabolism · doi:10.1186/1743-7075-1-2 · Cited by 122
Ketogenic diet for the treatment of pediatric epilepsy: review and meta-analysis
Sourbron, J., Klinkenberg, S., van Kuijk, S. M. J., Lagae, L., Lambrechts, D., Braakman, H. M. H., & Majoie, M. (2020) · Child's Nervous System · doi:10.1007/s00381-020-04578-7 · Cited by 111
Cited by
Barberio, B., Bertin, L., Facchin, S., Bonazzi, E., Cusano, S., Romanelli, G., Pesenti, F. F., Cazzaniga, E., Palestini, P., Zingone, F., et al. (2025) · Nutrients · doi:10.3390/nu17111879 · Cited by 28
Metadata
- Authors
- Dyńka, D., Kowalcze, K., & Paziewska, A.
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2022-11-24
- Volume
- 14
- Issue
- 23
- Pages
- 5003
- ISSN
- 2072-6643 (ISSN-L)
- OpenAlex
- W4310038333
- Cited by
- 215
- References
- 37
- FWCI
- 21.82
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.